United States in vitro and in vivo diagnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

In Vitro And In Vivo Diagnostic Substances Stocks in USA: Revenue Cohort 1

Name: In Vitro And In Vivo Diagnostic Substances Stocks in USA: Revenue Cohort 1 comparison snapshot
Creator: Fliar BI Prism

A five-company in vitro and in vivo diagnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderIDEXX · 48

Strongest available pathLantheus · +293.1%

Widest latest marginIDEXX · 24.6%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1IDXX · Nasdaq

IDEXX

A U.S.-listed issuer classified by the SEC in In Vitro And In Vivo Diagnostic Substances

Founded 1983Westbrook$43.91B market cap

View full Companies Radar profile

48Cautious

Snapshot price$556.7as of page date

Monthly-close return-10.5%five-year window

FY2025 revenue$4.30BIDEXX LABORATORIES INC /DE

Net margin24.6%FY2025

P/E snapshot39.2xone ratio, not a verdict

Prism attention5.6%share across these five

Filing track recordRevenue, USD billions

+33.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 7.6%

52-week position15% through range

$518.5$770.0

News mentions1.2K

Community mentions310partial coverage

U.S.-scope patents1651

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position14/100
Capital-event signal30/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 9 M&A involvements, 1 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 3 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2LNTH · Nasdaq

Lantheus

A U.S.-listed issuer classified by the SEC in In Vitro And In Vivo Diagnostic Substances

Founded 2008WILMINGTON$6.59B market cap

View full Companies Radar profile

40Cautious

Snapshot price$101.0as of page date

Monthly-close return+293.1%five-year window

FY2025 revenue$1.54BLantheus Holdings, Inc.

Net margin15.2%FY2025

P/E snapshot24.2xone ratio, not a verdict

Prism attention6.7%share across these five

Filing track recordRevenue, USD billions

+262.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 38.0%

52-week position82% through range

$49.67$111.9

News mentions1.4K

Community mentions0partial coverage

U.S.-scope patents650

Prism InsightsWhat sits behind the readiness signal
Observed risk 15/100higher means more observed risk

Earnings signal56/100
Management stability90/100
Market position23/100
Capital-event signal35/100
Innovation pulse13/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 17 M&A involvements, 7 asset-acquisition events and 15 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 11 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3BMRA · Nasdaq

Biomerica

A U.S.-listed issuer classified by the SEC in In Vitro And In Vivo Diagnostic Substances

Founded 1999Irvine, California$6.5M market cap

View full Companies Radar profile

39Cautious

Snapshot price$2.09as of page date

Monthly-close return-94.2%five-year window

FY2025 revenue$0.01BBIOMERICA INC

Net margin-93.6%FY2025

Prism attention75.2%share across these five

Filing track recordRevenue, USD billions

-26.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -7.3%

52-week position36% through range

$1.45$3.22

News mentions16.0K

Community mentions0partial coverage

U.S.-scope patents153

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal30/100
Management stability90/100
Market position0/100
Capital-event signal59/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4NTLA · Nasdaq

Intellia Therapeutics

A U.S.-listed issuer classified by the SEC in In Vitro And In Vivo Diagnostic Substances

Founded 2014Cambridge, Massachusetts$1.78B market cap

View full Companies Radar profile

39Cautious

Snapshot price$12.73as of page date

Monthly-close return-90.5%five-year window

FY2025 revenue$0.07BIntellia Therapeutics, Inc.

Net margin-609.9%FY2025

P/E snapshot-4.9xone ratio, not a verdict

Prism attention11.7%share across these five

Filing track recordRevenue, USD billions

+104.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 19.6%

52-week position24% through range

$7.95$28.25

News mentions2.5K

Community mentions120partial coverage

U.S.-scope patents871

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal48/100
Management stability90/100
Market position5/100
Capital-event signal29/100
Innovation pulse20/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 7 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5TKNO · Nasdaq

Teknova

A U.S.-listed issuer classified by the SEC in In Vitro And In Vivo Diagnostic Substances

Founded 1996Hollister, California$385.5M market cap

View full Companies Radar profile

38Cautious

Snapshot price$7.18as of page date

Monthly-close return-71.2%five-year window

FY2025 revenue$0.04BAlpha Teknova, Inc.

Net margin-42.6%FY2025

P/E snapshot-37.8xone ratio, not a verdict

Prism attention0.8%share across these five

Filing track recordRevenue, USD billions

+9.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.4%

52-week position89% through range

$1.91$7.84

News mentions173

Community mentions0partial coverage

U.S.-scope patents4

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position0/100
Capital-event signal15/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 2 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Lantheus

+293.1%

IDEXX

-10.5%

Teknova

-71.2%

Intellia Therapeutics

-90.5%

Biomerica

-94.2%

Latest revenue

USD billions, official filing scope shown on each company card.

IDEXX

$4.30B

Lantheus

$1.54B

Intellia Therapeutics

$0.07B

Teknova

$0.04B

Biomerica

$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

IDEXX

24.6%

Lantheus

15.2%

Teknova

-42.6%

Biomerica

-93.6%

Intellia Therapeutics

-609.9%

Prism news attention

Normalized share across these five names; attention is not quality.

Biomerica

75.2%

Intellia Therapeutics

11.7%

Lantheus

6.7%

IDEXX

5.6%

Teknova

0.8%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized in vitro and in vivo diagnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Biomerica leads the conversation

It holds 75.2% of measured in vitro and in vivo diagnostic substances news attention and also carries the basket's largest revenue base at $0.01B.

Price path

Lantheus leads the available price paths

Its monthly-close return is +293.1% for the five-year window. At the other end, Biomerica is -94.2% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

IDEXX has the widest latest margin

Its FY2025 net margin is 24.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Teknova shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -37.8x while its five-year window price return is -71.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · IDXX

IDEXX

1,194available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+65.8%257 latest 12m vs 155 prior 12m

Machine-classified coverage tone

95.9% positive+1.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

investment deal 42stock performance 21investment 16stock indices 13earnings report 10stock price 8earnings surprises 7annual earnings 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · LNTH

Lantheus

1,421available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-0.3%303 latest 12m vs 304 prior 12m

Machine-classified coverage tone

84.9% positive-8.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 26age prostate cancer 15cancer biomarkers 13share price 13vascetomy prostate cancer 12stock price 12diet prostate cancer 11obesity prostate cancer 10

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-17–2026-06-18 · trend and themes shown through 2026-06

Areas of research · BMRA

Biomerica

16,035available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Leadership & governance

Capital allocation & transactions

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+19.5%2,562 latest 12m vs 2,144 prior 12m

Machine-classified coverage tone

85.2% positive+9.9 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

mindfulness 759spiritual awakening 496cordless earphones 264mystical experience 258noise-cancelling headphones 224travel noise cancellation 196wireless noise cancelling 193office noise cancelling 192

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-30 · trend and themes shown through 2026-07

Areas of research · NTLA

Intellia Therapeutics

2,488available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Leadership & governance

Capital allocation & transactions

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+29.2%567 latest 12m vs 439 prior 12m

Machine-classified coverage tone

82.4% positive+11.2 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 168crispr-cas9 153crispr applications 138stem cell banking 58rare disease clinical trials 55gene therapy studies 53rare disease treatment 46gene delivery systems 42

Keyword tag occurrences in available Prism news records.

Coverage: 2012-04-05–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

IDXX

IDEXX

310 mentions

Stock and valuation

109

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 310 records remained after filtering.

NTLA

Intellia Therapeutics

120 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 120 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

IDXX

IDEXX

through 2026-02-04

Earnings releases 37Leadership changes 4M&A 4Business contracts 2Asset acquisitions 1

2026-02-04
Earnings releases
guidance to 2026 EPS of $14.29 to $14.80
2026-01-14
Leadership changes
On January 13, 2026, IDEXX Laboratories announced a planned CEO succession under which Michael (Mike) Erickson, PhD, will be promoted to President and Chief Executive Officer and appointed to the board effective May 12, 2026, while current President and CEO Jonathan (Jay) Mazelsky will become Executive Chair until his retirement following the company’s annual shareholder meeting in May 2027.
2025-12-04
Company announcements
IDXX shares climbed 14.8% on Nov. 3, after reporting its Q3 results. Its EPS came in at $3.40, surpassing Wall Street’s $3.14 estimate, while revenue of $1.11 billion exceeded expectations of $1.07 billion, driven by solid growth across its Companion Animal Group diagnostics segment and continued momentum in recurring services and consumables. Improved margins and strong demand for its diagnostic platforms supported earnings strength, prompting IDEXX to raise its full-year guidance.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LNTH

Lantheus

through 2026-02-12

Earnings releases 21M&A 12Lawsuits 10Business contracts 6Company announcements 6

2026-02-12
Company announcements
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to discuss its financial and operating results for the fourth quarter and full year of 2025.
2025-11-07
Lawsuits
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Lantheus Holdings, Inc.
2025-10-16
Leadership changes
Lantheus added Michelle Mathy as head of government affairs and public policy.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BMRA

Biomerica

through 2026-04-20

Earnings releases 11Leadership changes 10Business contracts 2Listing / IPO 2

2026-04-20
Earnings releases
Biomerica Inc. appears to still be finding its footing in expanding its contract development and manufacturing services, as seen in its fiscal third-quarter earnings. The Irvine-based biomedical technology company, which makes diagnostic solutions with a focus on gastrointestinal and inflammatory diseases, last week reported a 12% drop in net sales to $987,000 while net loss widened to $1.31 million from $1.16 million.
2026-02-26
Leadership changes
He is also a Board Observer at Biomerica, Inc. (Nasdaq: BMRA) and a Director of Insurance Income Strategies, Ltd.
2024-05-31
Business contracts
Biomerica has entered into an at‑market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NTLA

Intellia Therapeutics

through 2026-04-27

Company announcements 9Earnings releases 6Leadership changes 4Lawsuits 2Listing / IPO 2

2026-04-27
Listing / IPO
Intellia Therapeutics, Inc. (Nasdaq: NTLA ), ... announced that it has commenced an underwritten public offering of $150 million of shares of its common stock.
2026-04-03
Company announcements
today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia’s 2024 Inducement Plan, as amended.
2026-02-26
Earnings releases
Collaboration revenue was $23.0 million for the fourth quarter of 2025, compared to $12.9 million for the fourth quarter of 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TKNO

Teknova

through 2025-11-06

Earnings releases 2

2025-11-06
Earnings releases
Teknova reiterates its fiscal 2025 outlook for revenue and Free Cash Outflow. The Company continues to anticipate total revenue of $39 million to $42 million for the fiscal year ending December 31, 2025.
2024-07-09
Earnings releases
Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

In Vitro And In Vivo Diagnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary in vitro and in vivo diagnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

in vitro diagnostics market

38 sources65.0% extraction confidence

2023 extracted base$45.48B–$130.10B

2033 extracted forecast$85.21B–$157.56B

Implied source CAGR4.8%

new productsCOVID-19M&A activity

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, U.S., North America, Europe. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. In Vitro And In Vivo Diagnostic Substances news pulse

40,513available Prism news records

Latest 12m volume+15.4%17860 vs 15482 records

Positive classified tone50.0%+9.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching diagnostic, substance, vitro, vivo. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cancer survivorship lifestyle adjustments

7,348

psychosocial support in cancer care

5,709

harm reduction strategies

4,078

cancer-related fatigue management

3,919

substance abuse education

3,736

opioid addiction and treatment

3,643

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

support groups cancer 2,065mind-altering drug consumption 1,795post-covid complications 1,713opioid diversion abuse 1,702fentanyl treatment programs 1,648drug overdose 1,578counseling oncology 1,415diagnostic biotechnology 1,333

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

new products

38 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cancer survivorship lifestyle adjustments

7,348 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,514 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

unfavourable reimbursement scenario

1,217 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+15.4% news volume

The latest 12 months contain 17,860 matched records versus 15,482 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

50.0% positive · +9.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2835 (In Vitro And In Vivo Diagnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 1–8. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party In Vitro And In Vivo Diagnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

IDEXX leads the readiness ranking

Its Prism readiness score is 48/100, the highest in this five-company comparison.

Open IDEXX in Companies Radar

Scale and margin leadership sit with IDEXX and IDEXX

IDEXX has the largest displayed latest revenue at $4.30B; IDEXX has the widest displayed latest margin at 24.6%.

Open IDEXX in Companies Radar

Comparisons

Strongest versus weakest available price path

Lantheus is +293.1% for its five-year window; Biomerica is -94.2% for its five-year window.

Open Lantheus in Companies Radar Open Biomerica in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $4.30B for IDEXX to $0.01B for Biomerica. Entity and filing-period labels remain visible on the company cards.

Open IDEXX in Companies Radar Open Biomerica in Companies Radar

Anomalies

IDEXX has the widest attention-readiness rank gap

It ranks #4 by measured news attention (5.6%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open IDEXX in Companies Radar

Intellia Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +104.7% while its available monthly-close return is -90.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Intellia Therapeutics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Biomerica's 75.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Biomerica in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open IDEXX's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 48/100 score.

Open IDEXX in Companies Radar

Stress-test the largest divergence before forming a view

Compare Intellia Therapeutics's profile with Lantheus's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Intellia Therapeutics in Companies Radar Open Lantheus in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.